Anti-plasma kallikrein monoclonal antibody
Lanadelumab
Brand names: Takhzyro
Adult dose
Dose: 300mg SC every 2 weeks; consider every 4 weeks if attack-free
Route: SC
Frequency: q2w
Clinical pearls
- Long-term prophylaxis of HAE attacks (≥12y)
- Specialist immunology
Contraindications
- Hypersensitivity
Side effects
- Injection site reactions
- Headache
- Hypersensitivity
Monitoring
- Attack frequency
Reference: BNF; NICE TA606; SmPC; https://bnf.nice.org.uk/drugs/lanadelumab/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- PLASMIC Score for TTP · Haematological Diagnosis
- Fresh Frozen Plasma (FFP) Dose Calculator · Transfusion Medicine
- Multiple Myeloma Diagnostic Criteria (CRAB + SLiM-CRAB) · Haematological Malignancy
- Erasmus GBS Outcome Score (EGOS) · Guillain-Barre Syndrome
Pathways
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
- Syncope Assessment · ESC 2018 Syncope Guidelines; NICE NG109
- Acute Chest Pain · NICE CG95; ESC 2023 ACS Guidelines